---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-390539"
form_type: "8-K"
ticker: "BNTC"
cik: "0001808898"
company_name: "Benitec Biopharma Inc."
filed_at: "2026-09-14T20:04:48+00:00"
generated_at: "2026-09-14T20:06:38.713707+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Benitec FY2026 net loss $45.5M; BB-301 cohorts complete follow-up, FDA meeting held

## Summary
- FY2026 net loss attributable to shareholders was $45.5M ($0.98/share), vs $37.9M ($1.05/share) in FY2025.
- Total expenses rose to $51.2M from $41.8M; R&D up to $23.4M, G&A up to $27.8M.
- Cash and equivalents $180.0M at June 30, 2026.
- All six Cohort 1 low-dose BB-301 patients completed 12-month follow-up; Cohort 2 fully enrolled, all treated safely.
- Type C FDA meeting held in 3Q2026 on BB-301 pivotal design; minutes expected in October; pivotal trial init planned mid-2027.

## SEC filing metadata
- accession: 0001193125-26-390539
- form_type: 8-K
- ticker: BNTC
- cik: 0001808898
- company_name: Benitec Biopharma Inc.
- filed_at: 2026-09-14T20:04:48+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/0001193125-26-390539-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1808898/000119312526390539/bntc-20260914.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-390539
- JSON: https://secwatch.observer/filing/0001193125-26-390539.json
- Plain text: https://secwatch.observer/filing/0001193125-26-390539.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.